Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will participate in The Twelfth London International Cough Symposium on July 13-14, 2022. The event will focus on advancements related to acute and chronic cough, including novel treatments. Trevi is developing Haduvio (oral nalbuphine ER) aimed at treating prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has received Fast Track designation from the FDA for reducing pruritus in affected adults, though its efficacy is yet to be evaluated by regulatory authorities.
Trevi Therapeutics (TRVI) announced positive results from its Phase 2b/3 PRISM trial evaluating Haduvio for treating prurigo nodularis. The trial achieved statistical significance with a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) for 25% of Haduvio patients compared to 14% for placebo (p=0.0157). Key secondary endpoints were also met. The drug's safety profile was consistent with prior studies. Topline results will be discussed in a conference call on June 29, 2022, at 8:30 am EDT, highlighting Haduvio's potential in addressing severe itching and enhancing quality of life.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced that its President and CEO, Jennifer Good, will present at the 2022 BIO International Convention on June 13 at 4 PM PT in San Diego, CA. The convention is expected to attract over 15,000 leaders in biotechnology and pharma, focusing on networking and partnership opportunities. Trevi is developing Haduvio™, an investigational therapy for pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis, and is currently conducting Phase 2b/3 and Phase 2 clinical trials for these conditions.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced significant advancements in its clinical development for Haduvio, targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and chronic pruritus in prurigo nodularis (PN). The Phase 2 CANAL trial demonstrated a 77.3% reduction in cough frequency, leading to expedited development. The company completed a private placement raising $55 million to fund further clinical trials. As of March 31, 2022, Trevi reported $29.1 million in cash and cash equivalents and a net loss of $7.3 million for the quarter.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call on May 12, 2022, at 4:30 p.m. EDT to discuss its Q1 2022 financial results and provide a corporate update. The call can be accessed via phone or through a live audio webcast on the company's website. Trevi is focused on developing Haduvio™, an investigational therapy aimed at treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. Haduvio has received Fast Track designation from the FDA for its proposed indication.
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will present at two significant events in May 2022. The LifeSci Partners Immunology & Inflammation Symposium is scheduled for May 11, featuring Jennifer Good (President and CEO) and Dr. Bill Forbes (CDO). Additionally, Trevi will participate in the H.C. Wainwright Global Investment Conference from May 23-26, with a virtual presentation on May 24. Trevi is developing Haduvio (nalbuphine ER) for treating chronic pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT. CEO Jennifer Good and Dr. Bill Forbes will discuss the investigational therapy Haduvio for treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. The event will be available via live webcast on the company’s website, with an archived replay accessible for 30 days.
Trevi recently reported significant results from its CANAL trial, showing a 77% reduction in daytime cough frequency.
Trevi Therapeutics (Nasdaq: TRVI) announced a private placement to raise approximately $55 million through the sale of 4,580,526 shares at $1.90 each and pre-funded warrants at $1.899. The funds will support the clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis (IPF) and for working capital. The deal, led by Frazier Life Sciences and Venrock Healthcare Capital Partners, is expected to close around April 11, 2022, pending customary conditions. The shares are unregistered under the Securities Act and will be resold upon effective registration.
Trevi Therapeutics (TRVI) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022. The fireside chat, featuring CEO Jennifer Good and CDO Bill Forbes, will take place from 8:00 a.m. to 8:40 a.m. EDT. The discussion will highlight findings from the Phase 2 CANAL trial, where Haduvio showed a 77% reduction in daytime cough frequency in patients with idiopathic pulmonary fibrosis. Additionally, top-line data from the Phase 2b/3 PRISM trial for pruritus in prurigo nodularis is anticipated in the second quarter of 2022.
Trevi Therapeutics (TRVI) announced a webinar on March 30, 2022, focusing on chronic cough in idiopathic pulmonary fibrosis (IPF) patients. Dr. William Forbes will discuss the challenges faced by IPF patients, including a lack of approved treatments for chronic cough, which affects up to 85% of the 130,000 estimated US patients. Trevi will present recent positive interim results from its Phase 2 CANAL trial of Haduvio (nalbuphine ER) aimed at addressing chronic cough in IPF. The webinar will also include a live Q&A session.
FAQ
What is the current stock price of Trevi Therapeutics (TRVI)?
What is the market cap of Trevi Therapeutics (TRVI)?
